EXPERIENCE OF ADMINISTRATION OF CANAKINUMAB, AN INTERLEUKIN 1β INHIBITOR, IN A PATIENT WITH CHRONIC TOPHACACEOUS GOUT
This article reports a clinical case of administration of canakinumab (Ilaris®), an interleukin-1β inhibitor, in a patient with chronic tophacaceous gout resistant to therapy with nonsteroidal anti-inflammatory drugs, glucocorticoids, and colchicine. The results show a good and long-term clinical ef...
Saved in:
Main Authors: | Maksim Sergeyevna Eliseev, O V Zhelyabin, V G Barskova, E L Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2014-03-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/1365 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience with canakinumab in a patient with gout and IgA nephropathy
by: E. V. Ilyinykh, et al.
Published: (2019-09-01) -
Therapy with canakinumab for gout
by: M. S. Eliseev, et al.
Published: (2019-04-01) -
Clinical experience with the interleukin-1β blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopurinol is used
by: M. S. Eliseev, et al.
Published: (2015-06-01) -
Gout in history of humanity
by: M. S. Eliseev, et al.
Published: (2024-06-01) -
Assessment of cardiovascular risk from the use of an interleukin-1 inhibitor in patients with severe tophaceous gout
by: M. S. Eliseev, et al.
Published: (2016-03-01)